ARTIDIS

The company’s lead product, the ARTIDIS nanomechanical analysis platform, has demonstrated rapid (<3 hours), objective measurement of suspicious breast lesions at the bedside. Ongoing clinical studies are evaluating its ability to predict tumor type, aggressiveness, and neoadjuvant therapy response compared to standard histopathology. Early results support significant reduction in diagnostic time and potential for improved personalized treatment planning. "This prospective...study aims to test the performance of nanomechanical phenotype in predicting tumor type, tumor aggressiveness, and neoadjuvant treatment response compared to the gold standard of histopathological assessment." No published pivotal trial results as of June 2025.